-
Bristol-Myers Oncology Growth Potential Remains High
Wednesday, February 22, 2017 - 11:06am | 369Read More...Bristol-Myers Squibb Co (NYSE: BMY) “has named three independent directors to its board amid reports that JANA Partners and Carl Icahn have taken stakes in BMY,” said Argus’ David Toung in a note, while reiterating a Buy rating on the company, with a price target of $75. Board...
-
The Fate Of Humana Rests In The Hands Of A Federal Judge
Tuesday, January 17, 2017 - 10:41am | 302Read More...Humana Inc (NYSE: HUM) shareholders are watching and waiting patiently for a federal judge to determine the fate of the proposed mega-merger between Humana and Aetna Inc (NYSE: AET). The U.S. Department of Justice filed suit to block the merger on antitrust grounds, and both sides presented closing...
-
Trump's Election Could Clear The Way For The Aetna-Humana Merger
Tuesday, November 15, 2016 - 11:48am | 331Read More...President-elect Donald Trump's victory spells higher chances for the regulatory approval of the merger between Aetna Inc (NYSE: AET) and Humana Inc (NYSE: HUM), Argus’ David Toung said in a report. He maintains a Buy rating on Aetna, while raising the price target from $130 to $145....
-
Allscripts Posts Its Sixth Straight Quarter Of New Order Growth
Friday, October 21, 2016 - 3:49pm | 298Read More...Argus reiterated its Buy rating on Allscripts Healthcare Solutions Inc (NASDAQ: MDRX) with a $19 target price as it believes new orders will translate into higher revenue over the next 12–18 months. “In particular, we are encouraged by the continuing trend of new orders growing faster...
-
Johnson & Johnson's Robust Pipeline Supports Its Above-Average Valuation
Wednesday, October 19, 2016 - 12:07pm | 343Read More...While noting that the shares of Johnson & Johnson (NYSE: JNJ) trade at a premium to Argus' universe of pharmaceutical stocks, the firm said the valuation is justified, given its robust new drug pipeline, improving device business and expanding opportunities in its consumer businesses. 3Q Review...
-
Becton Dickinson Shares Favorably Valued As It Works To Boost Earnings
Tuesday, October 18, 2016 - 11:12am | 321Read More...Argus believes that shares of Becton Dickinson and Co (NYSE: BDX) are favorably valued as it reaffirmed its Buy rating and $185 target price. Analyst David Toung welcomed the company’s sale of Respiratory Solutions and spinal product businesses, a move that will enable Becton Dickinson to...
-
Extended Contracts Should Boost The Top-Line For AmerisourceBergen Corp
Thursday, October 13, 2016 - 9:23am | 423Read More...Argus reaffirmed its Buy rating and $135 price target on AmerisourceBergen Corp. (NYSE: ABC) shares as the extension of contracts with Kaiser Permanente and Express Scripts Holding Company (NASDAQ: ESRX) should boost revenue. Kaiser and Express are two of ABC’s largest customers, with Express...
-
Allergan's New Products And Robust R&D Pipeline Support A Positive Long-Term View
Monday, October 3, 2016 - 10:31am | 251Read More...Expressing positivity regarding the long-term growth opportunities for Allergan plc Ordinary Shares (NYSE: AGN), Argus’ David Toung mentioned the company’s growth was expected to be driven by its key franchises, other aesthetic products, eye care solutions and gastrointestinal drugs...
-
Zimmer Biomet Is In Position To Ramp Up Revenue Growth
Wednesday, September 21, 2016 - 9:42am | 310Read More...Following the upbeat 2016 guidance issued by Zimmer Biomet Holdings Inc (NYSE: ZBH), Argus’ David Toung believes the company has completed its merger integration process and the combined sales force has stabilized. Toung reiterated a Buy rating on the company, with a price target of $140...
-
Generic Drug Price Deflation Is Weighing On McKesson Shares
Monday, September 19, 2016 - 11:19am | 345Read More...McKesson Corporation (NYSE: MCK) shares have declined 6.4 percent over the last three months, underperforming the shares of its key rivals. Argus’ David Toung maintains a Hold rating on the company. Price Deflation “We believe that concerns about generic price deflation and reduced...
-
With Solid Growth And Strong Pipeline, Argus Is Positive On Celgene's Long-Term Prospects
Tuesday, September 6, 2016 - 3:55pm | 240Read More...In a report issued Tuesday, Argus analyst David Toung shared a look into Focus List-selected Celgene Corporation (NASDAQ: CELG), reiterating a Buy rating and $155 price target. The expert argued that the company has not only managed to generate robust growth from its pharmaceuticals portfolio,...
-
Argus Upgrades Boston Scientific, Sees Market Share Gains And Strong Growth Ahead
Thursday, September 1, 2016 - 10:27am | 266Read More...Boston Scientific Corporation (NYSE: BSX) shares are trading marginally above its peer multiple, which Argus’ David Toung believes still makes the stock attractive, given the company’s robust growth prospects. Toung upgraded the rating on Boston Scientific from Hold to Buy with a price...
-
St. Jude's Abbott Merger On Track For Q4
Friday, August 26, 2016 - 9:02am | 273Read More...St. Jude Medical, Inc. (NYSE: STJ) expects to complete its merger with Abbott Laboratories (NYSE: ABT) by yearend 2016. Argus’s David Toung maintained a Hold rating on St. Jude, citing the pending acquisition. St. Jude reported its Q2 adjusted EPS at $1.06, up from $1.03 a year earlier....
-
Express Scripts Margins Could Face Downward Pressure From Less Prescription Growth
Wednesday, August 24, 2016 - 11:42am | 401Read More...Argus' David Toung reiterated Express Scripts Holding Company (NASDAQ: ESRX)'s Hold rating after forecasting slow prescription growth for the company. The analyst acknowledged the company's hike on 2016 EPS guidance, but noted the increase was mainly driven by a lower share count rather than a...
-
Argus Talks Humana-Aetna Deal Uncertainty, Raises EPS Estimates For Humana
Monday, August 22, 2016 - 10:48am | 386Read More...The U.S. Department of Justice has brought legal action to block the merger between Humana Inc (NYSE: HUM) and Aetna Inc (NYSE: AET) on antitrust grounds. Argus’ David Toung maintains a Hold rating on Humana. DoJ Lawsuit The lawsuit by the Justice Department creates meaningful uncertainty...
